August 11, 2015
A recent study was conducted on patient satisfaction following treatment Juvederm Voluma XC, a popular hyaluronic acid filler used to correct age-related midface volume deficit.
The study was headed by Julius Few, MD at the University of Chicago Pritzker School of Medicine and involved 235 patients with moderate to severe age-related midface volume deficit (MVD). Patients filled out quarterly evaluations rating treatment outcomes on the Global Aesthetic Improvement Scale, overall satisfaction with facial appearance, satisfaction with the midface region, look and feel of the midface, achievement of treatment goal and self-perception of age.
The mean injection volume for initial treatment of Voluma was 5.09 mL and 1.93 mL of for touch-up treatment. At six months, 92.8% of patients rated their cheek volume as improved or much improved based on their survey results. Two years following intial treatment, survey results showed a 79% satisfaction rating. Treatment goals were achieved by 67.8% of patients at six months and 49% at two years.
On average, patients reported looking 5 years younger at the six month mark and 3 years younger at 2 years. The most common adverse treatment responses included mild to moderate tenderness, swelling, firmness and lumps or bumps that lasted up to two weeks in certain cases.
“The study is one of the first of its kind to focus on patients’ perspective of satisfaction for a non-invasive facial procedure,” Dr. Few tells Cosmetic Surgery Times. “The results show that patients actually rated their feeling of improvement higher than the study’s evaluators did.”
The study appears in Aesthetic Surgery Journal.Tags: aging, allergan, dermal filler, injectables, juvederm voluma, midface, volume loss
This post was written by Jenny Yergensen